NEW_CURA-LEAF_1170x120_OCT

Olivier Brandicourt

FDA approves asthma indication for Dupixent (dupilumab)

FDA approves asthma indication for Dupixent (dupilumab)

TARRYTOWN, N.Y. and PARIS — Regeneron Pharmaceuticals, Inc. and Sanofi today announced the U.S. Food and Drug Administration has approved Dupixent (dupilumab) as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma. Dupixent inhibits the overactive signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13),

Sanofi to acquire Bioverativ for $11.6 billion

Sanofi to acquire Bioverativ for $11.6 billion

PARIS — Sanofi plans to buy biopharmaceutical company Bioverativ Inc. in a deal valued at $11.6 billion. Waltham, Mass.-based Bioverativ specializes in therapies for hemophilia and other rare blood disorders. Sanofi said Monday that the addition of Bioverativ will boost its presence in specialty care and leadership in rare diseases as well as provide an expansion platform

Amgen CEO elected as PhRMA chairman

Amgen CEO elected as PhRMA chairman

WASHINGTON — Pharmaceutical Research and Manufacturers of America (PhRMA) has named Amgen Inc. chairman and chief executive officer Robert Bradway as chairman-elect. Bradway will succeed Joaquin Duato, executive vice president and worldwide chairman of pharmaceuticals at Johnson & Johnson, as PhRMA chairman in February 2018. Previously, Bradway served as board treasurer for PhRMA. Sanofi CEO

Sanofi names Main to lead new consumer health unit

Sanofi names Main to lead new consumer health unit

PARIS — Sanofi has appointed former Bayer executive Alan Main as executive vice president of its newly formed Consumer HealthCare global business unit. Sanofi said Friday that Main, who also joins its executive committee, will be responsible for building and maintaining the company’s position in the consumer health care market, including the expected integration of

Sanofi, Boehringer Ingelheim mull business swap

Sanofi, Boehringer Ingelheim mull business swap

NEW YORK — Sanofi and Boehringer Ingelheim are in talks to swap their animal health and consumer health care businesses, respectively. The companies said Tuesday that the proposed transaction would involve an exchange of Sanofi’s Merial animal health business (“Merial”), valued at €11.4 billion ($12.45 billion U.S.), and Boehringer Ingelheim’s consumer health care business,valued at €6.7 billion ($7.32 billion U.S.).

Sanofi, Google team up to improve diabetes care

Sanofi, Google team up to improve diabetes care

PARIS and MOUNTAIN VIEW, Calif. — Sanofi and the life sciences team at Google have formed a collaboration to improve care and outcomes for people with type 1 and type 2 diabetes. The companies said the alliance will pair Sanofi’s leadership in diabetes treatments and devices with Google’s expertise in analytics, miniaturized electronics and low-power chip